Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Kswdeluxon Nov 20, 2022 2:16pm
220 Views
Post# 35113961

RE:RE:RE:Is a deal/buyout in 2022 realistic?

RE:RE:RE:Is a deal/buyout in 2022 realistic?

fox7mf wrote: I think most would agree with much of what you assert Ksw...except, there are those who believe PFE have been in possession of final Bracelet data for quite sometime, and may, in fact, be nearing the end of their exclusivity/right of first refusal. Of course, this is a moot pt regarding a Roche offer...they'll do so regardless, and I imagine within 60 days.

 

That woukd be great if Pfuzer has receied the final data. I know they have been working with real time data. But Matt stated they are letting the data mature until Q1 2023. Maybe that is a second data set that will be used for Phase III registration. 

its all a bit confusing to say the least.

I hope you are right, because that would definitely shorten the decussion making tine period with Roche on their heels.

Based on that 60 dats would be more reasonable and mayveca very Merry Christmas.

cheers!
 

<< Previous
Bullboard Posts
Next >>